Group 1 - The company, Gilead Sciences, announced the completion of the first cohort of a 12-week Phase IIa study in the United States for its small molecule GLP-1R agonist ASC30, which is administered as a once-monthly subcutaneous depot formulation for overweight or obese subjects [1]